IL6 and COVID-19: The forthcoming results of a phase III randomized controlled study sponsored by Hoffmann-La Roche (COVACTA, NCT04320615) may provide more valid clinical evidence and understanding of anti-IL-6 signaling agent usage in patients with COVID-19.